Table 1 Characteristics of included RCTs on intradermal versus intramuscular administration of influenza vaccine
Authors | Country | Interventions | Units of treatment ID/IM | Immunogenicity | Reported reactions | Population | Quality score | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Seroprotection | Seroconversion | Injection sitea | Systemicb | Jadad scale | Chalmers scale | ||||||||||
A/H1N1 | A/H3N2 | B | A/H1N1 | A/H3N2 | B | ||||||||||
ID | IM | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | ||||||
ID/IM | ID/IM | ID/IM | ID/IM | ID/IM | ID/IM | ID/IM | ID/IM | ||||||||
L Gelinck et al. 2009 [14] | Netherlands | TIV SU | TIV SU | 77/79 | 49(63.6)/60(75.9) | 60(77.9)/58(73.4) | 50(64.9)/55(69.6) | NA | NA | NA | Total reactionsc | Immuno-compromized patients | 3/5 | 0.54 | |
3 μg HA/strain | 15 μg HA/strain | 52 % ID group/30 % IM group | |||||||||||||
Y Jo et al. 2009 [15] | Korea | TIV SPL | TIV SPL | 52/55 | 50(96.1)/52(94.5) | 50(90.1)/54(98.1) | 41(78.8)/ 45(81.8) | 38(73)/41(74.5) | 28(53.8)/24(43.6) | 28(53.8)/37(67.3) | 10 (19)/3(5.5)d | 1 (1.9)/2 (3.6)e | Patients with solid cancer | 2/5 | 0.32 |
7.5 μg HA/strain | 15 μg HA/strain | ||||||||||||||
E Morelon et al. 2010 [16] | France | TIV SPL | TIV SPL | 31/31 | 22(71)/16(52) | 16(52)/11(36) | 22(71)/19(61) | 11(35)/6(19) | 11(35)/6(19) | 6(19)/6(19) | 25 (80.6)/ 15 (48.4) | 17 (54.8)/16 (51.6) | Renal transplant patients | 3/5 | 0.45 |
15 μg HA/strain | 15 μg HA/strain | ||||||||||||||
O Manuel et al. 2011 [17] | Multicentricf | TIV SPL | TIV SPL | 41/43 | 16(39)/ 12(28) | 34(83)/ 42(98) | 12(29)/ 25(58) | 3(7.3)/ 3(7) | 2(4.9)/3(7) | 3(7.3)/5(11.6) | 17 (41.5)/11 (25) | 3 (7.3)/7 (15.9) | Lung transplant patients | 3/5 | 0.67 |
6h μg HA/strain | 15 μg HA/strain | ||||||||||||||
F Ansaldi et al. 2012 [18] | Italy | TIV SPL | TIV SPL | 28/24 | 22(79)/19(80) | 23(82)/19(80) | 21(75)/18(76) | 14(50)/15(64) | 15(54)/14(60) | 11(36)/ 8(32) | 18 (64.3)/5 (20.8) | 6 (21.4)/3 (12.5)g | HIV-infected patients | 3/5 | 0.71 |
9 μg HA/strain | 15 μg HA/strain | ||||||||||||||
A Baluch et al. 2013 [19] | Canada | TIV SPL | TIV SPL | 107/105 | 76(71)/74(70.5) | 75(70.1)/67(63.8) | 68(63.6)/55(52.4) | 40(37.4)/36(34.3) | 31(29)/32(30.5) | 23(21.5)/18(17.1) | NA | Transplant patients | 3/5 | 0.75 | |
9i μg HA/strain | 15 μg HA/strain | ||||||||||||||